{"id":"W3215637673","doi":"10.1182/blood-2021-153795","title":"Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Medicine; Ponatinib; Internal medicine; Acute lymphocytic leukemia; Philadelphia chromosome; Oncology; Hematopoietic stem cell transplantation; Chemotherapy; Chemotherapy regimen; Clinical endpoint; Gastroenterology; Leukemia; Myeloid leukemia; Transplantation; Lymphoblastic Leukemia; Nilotinib; Clinical trial; Imatinib","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001798954,0.0002691284,0.0007552935,0.0002234526,0.000110002,0.00001197348,0.0001431244,0.0001257165,0.00002154562],"category_scores_gemma":[0.0005489309,0.0002144559,0.00007173068,0.0006863007,0.0001924716,0.0001017466,0.0002229551,0.0001596209,0.000001174229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002248475,"about_ca_system_score_gemma":0.00151515,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004486686,"about_ca_topic_score_gemma":0.00001490918,"domain_scores_codex":[0.9975417,0.00007901069,0.0006628386,0.0005769947,0.0007589434,0.0003805412],"domain_scores_gemma":[0.9971212,0.000395356,0.0003236249,0.0004913047,0.001457448,0.0002111354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2261321,0.3401029,0.03486696,0.003431438,0.03237746,0.006401379,0.02776621,0.00009399791,0.3088745,0.0003614573,0.009306071,0.0102856],"study_design_scores_gemma":[0.6751296,0.1035339,0.0390996,0.0009298464,0.005851042,0.0004363517,0.001597979,0.002234277,0.1704542,0.00004386671,0.0001344107,0.0005550107],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9964978,0.00009127246,0.00006220573,0.0001661327,0.00003816457,0.00172509,0.001195188,0.0000297903,0.0001943812],"genre_scores_gemma":[0.9977756,0.00001835822,0.001100346,0.00004497427,0.00005150083,0.00007584746,0.0007224058,0.00005164074,0.0001593895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4489976,"threshold_uncertainty_score":0.8745257,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01112127825041482,"score_gpt":0.2829699702927426,"score_spread":0.2718486920423278,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}